Psyence Group, Author at Psyence

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Psyence Group2024-10-29T13:47:02+02:00September 20, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that it has entered into a conditional share sale agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or "PBM") (as purchaser) for the disposal by Psyence Group of its 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development ("Proposed Transaction"). Per the terms of the Proposed Transaction,

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group2024-10-29T13:47:18+02:00September 19, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Group2024-10-29T13:47:31+02:00September 16, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Group2024-07-30T10:30:31+02:00July 30, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group2024-05-06T14:54:38+02:00May 6, 2024|Investor Information, Psychedelic News, Press Releases|

Psyence Biomedical Ltd has announced that its Australian subsidiary, Psyence Australia Pty Ltd ("Psyence Australia"), has entered into a partnership with Fluence,

Psyence Group Provides Corporate Update Following Succesful SPAC Spin Out Of Therapeutic Division

Psyence Group2024-03-11T14:36:36+02:00March 11, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Biomed II Corp. ("Psyence Biomed"), the therapeutics division of Psyence Group and target business of the Business Combination, is now a wholly-owned subsidiary of NASDAQ traded PBM.

Psyence Biomedical Ltd. Approved to List on Nasdaq

Psyence Group2024-03-11T09:59:22+02:00January 26, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence announce the completion of its subsidiary Psyence Biomedical Ltd’s (“Psyence Biomed”) merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company.

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

Psyence Group2024-03-11T09:59:55+02:00January 16, 2024|Investor Information, Psychedelic News, Press Releases|

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing [...]

Psyence Group Announces SEC Effectiveness Of F-4 For Proposed Business Combination Between Subsidiary And NASDAQ Listed Newcourt Acquisitions Corp

Psyence Group2023-11-15T20:55:16+02:00November 15, 2023|Press Releases, Investor Information|

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”) was declared effective by the SEC on November 13, 2023.

Psyence Production Expands Capability

Psyence Group2023-10-30T18:07:59+02:00October 30, 2023|Press Releases, Psychedelic News|

Psyence recently designed a new laboratory at the facility in order to expand its extraction capabilities. The building of the laboratory has since commenced and is expected to be completed in Q4 2023. The expansion fits under the existing building footprint, and once completed, new state-of-the-art extraction equipment will be installed to enhance its current extraction capabilities. There are multiple potential benefits to on-site extraction including increased product shelf life, a more stabilized format for export, and reduced transport costs.

Psyence Group

About Psyence Group